

In re application of: Chung-Il HONG et al.

Appl. No.: 10/538,636

Int'l Application No.: PCT/KR2003/002700

Int'l Filing Date: December 10, 2003

Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Filed: June 10, 2005

Atty. Docket No.: 36470-218722

Customer No.

26694 PATENT TRADEMARK OFFICE

For: ORAL FORMULATIONS FOR POORLY ABSORPTIVE

HYDROPHILIC DRUGS

SUPPLEMENTAL Information Disclosure Statement

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 Attention: PCT DO/EO/US

Sir

This is an Information Disclosure Statement submitted within the time limit specified under 37 C.F.R. § 1.97(b). It supplements the INFORMATION DISCLOSURE STATEMENT filed June 9, 2005.

Copies of A20 and A21 are enclosed herewith. In the second paragraph, last sentence [of the June 9, 2005 IDS], applicants noted that these two reference would be submitted in the near fitture.

Please charge any necessary fee, or credit any overpayment in connection with this Information Disclosure Statement to Deposit Account No. 22-0261.

Respectfülly submitted.

Registration No. 26,032 VENABLE LLP

P.O. Box 34385 Washington, D.C. 20043-9998

Telephone: (202) 344-4000 Telefax: (202) 344-8300

677225

Approved for use through 10/31/2002 OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it contains a valid OMB contains.

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/538,636
Filing Date June 10, 2005
First Named Inventor Chung-II HONG et al.
Group Art Unit Unassigned
Exeminer Name Unassigned Unassigned Attorney Docket Number 36470-218722

(use as many sheets as necessary)
Sheet I of I

U.S. PATENT DOCUMENTS							
Examiner Initials *	Cite No.1	U.S. Pa	itent Document	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevan	
		Number Kind Code ² (if known)		Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relev Passages or Relevant Figures Appear	
		-					
	-	_					
	-						
	-						

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	For Office ³	eign Patent Doo Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₀
	A20	WO	98/01159		ILLUM	01/15/1998		
				+				
			-	+	_			
			i e					

		PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), bublisher (city and/or country where published.					
	A21	E. Scott Swenson et al., "(C) Means to Enhance Penetration; (2) Intestinal Permeability Enhancement For Proteins, Peptides, and Other Polar Drugs: Mechanisms and Potential Toxicity". Advanced Drug Deliyery Reviews. 8, 1992. pages 39-92.					
Examiner Signature		Date Considered					